ESTRO 2024 - Abstract Book

S2614

Clinical - Urology

ESTRO 2024

PSMA-PET can represent an optimal imaging modality to identify failure-sites and guide salvage treatments in PCa pts patients relapsing after RP+P-Bed RT.

Keywords: Prostate cancer, PSMA, SBRT

3062

Digital Poster

Salvage Radiotherapy after Failure of Primary Focal Therapy for prostate cancer:A Systematic Review

Mohamed Shelan 1 , Lucas mose 1 , Maiwand Ahmadsei 1 , Osama Mohamad 2 , Constantinos Zamboglou 3 , Luca Nicosia 4 , Thomas Zilli 5 , filippo alongi 4 , stefano arcangeli 6 , Matthias Guckenberger 7 , Daniel M. Aebersold 8 1 Inselspital, Bern University Hospital, University of Bern, Department of Radiation Oncology, Berne, Switzerland. 2 MD Anderson Cancer Center, Department of Radiation Oncology, Houston, USA. 3 Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Radiation Oncology, Freiburg, Germany. 4 IRCCS Ospedale Sacro Cuore Don Calabria, Advanced Radiation Oncology Department, Negrar di Valpolicella, Italy. 5 Oncology Institute of Southern Switzerland, EOC, Department of Radiation Oncology, Bellinzona, Switzerland. 6 Fondazione IRCCS San Gerardo Dei Tintori, Department of Radiation Oncology, Monza, Italy. 7 University Hospital Zürich, University of Zurich, Department of Radiation Oncology, Zurich, Switzerland. 8 Inselspital, Bern University Hospital, University of Bern, Department of Radiation Oncology, Zurich, Switzerland

Purpose/Objective:

This systematic review aimed to evaluate the evidence for salvage radiation therapy (SRT) in prostate cancer patients who underwent primary focal treatment, focusing on reported acute and late toxicities.

Material/Methods:

A comprehensive search was conducted in five electronic databases (PubMed, Scopus, Web of Science, Cochrane Library, Clinicaltrials.gov) from inception until 30th September 2023. Eligible publications included prostate cancer patients who underwent salvage radiotherapy after primary focal treatment. Primary outcomes included rates of grade ≥2 acute and late gastrointestinal (GI) and genitourinary (GU) toxicity based on the Common Terminology Criteria for Adverse Events (CTCAE) scale or Radiation Therapy Oncology Group (RTOG) scales.

Results:

A total of 19 studies were included, with 570 prostate cancer patients treated with SRT after primary focal management (high intensity focused ultrasound or Cryoablation). Median age was 68.4 years. Median time between primary focal treatment and SRT was 20 months. Most of the patients (90%) received conventionally fractionated